AZD3229是一种有效的、广泛的突变型酪氨酸激酶受体(KIT)抑制剂，可用于开发治疗胃肠道间质瘤。
CAS：2248003-60-1
分子式：C24H26FN7O3
分子量：479.51
纯度：98%
存储：Store at -20°C

Background:

AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines (GI50=1-50 nM). AZD3229 Tosylate demonstrates potent single digit nM growth inhibition across a broad cell panel, with good margin to KDR-driven effects. Selectivity over KDR can be rationalised predominantly by the interaction of water molecules with the protein and ligand in the active site and its kinome selectivity is similar to the best of the approved GIST agents[1].

[1]. Kettle JG, et al. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy) quinazolin-4-yl]amino} phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J Med Chem. 2018 Oct 11;61(19):8797-8810.